Less than two weeks after making a presentation at the SeeThruEquity Conference in Miami Beach, SeeThruEquity increased its price target for ChineseInvestors.com (OTCQB: CIIX) to $3.75. The previous price target for CIIX, issued in October 2016, was $2.05. SeeThruEquity delivers unbiased and unpaid for equity research for publicly traded companies with market capitalizations of less than $1 billion. The increased target price reflects the added potential from legal cannabis initiatives taken by ChineseInvestors.com. Though in the early stages of penetrating the legal cannabis market, ChineseInvestors.com has demonstrated prior success with its profitable investment in Medicine Man Technologies, generating $2.3 million in proceeds from stock sales of Medicine Man in 2016.

Traditionally, ChineseInvestors.com has delivered a broad range of products, services, and information for the Chinese speaking population, estimated at 1.2 billion people worldwide. The company provides real-time market commentary, analysis, and educational services in the Chinese language, and it offers several types of subscription-based services. Founded in 1999, the company is headquartered in Los Angeles with offices in New York City and Shanghai, China. ChineseInvestors.com also offers consultation services to private companies seeking to go public, as well as advertising and public relations services.

With a focus on value-added opportunities, the company has recently expanded into retail and online sales of cannabidiol (CBD) products. CBD is considered to have a broad range of potential medical applications, including the treatment of epilepsy. With multiple anecdotal claims of CDB efficacy in treating epilepsy, Great Britain-based GW Pharmaceuticals is seeking FDA approval to market a liquid formulation of pure plant-derived CBD. Clinical reports show CBD is devoid of the euphoric side effects associated with THC. ChineseInvestors.com markets CBD products to the Chinese people through its website, www.ChineseCBDoil.com.

Although early in market penetration, ChineseInvestors.com is among the very first to capitalize on selling CBD products to 1.2 billion Chinese people. The company has previously exhibited the ability to identify and execute upon opportunity. Given its track record, it should come as no surprise if CIIX succeeds in this new venue and, subsequently, achieves SeeThruEquity’s price target.

For more information, visit the company’s website at www.ChineseInvestors.com

Monaker Group, Inc. (OTCQB: MKGI) will present at the ROTH Conference on March 15, 2017. The 29th annual conference will be held March 13-15 in Dana Point, California, at the Ritz-Carlton. Monaker Group is a multi-tiered technology travel company targeting the high-end tourism market, the alternative lodging rental (ALR) industry, and business/leisure travelers.

Bill Kerby, chairman and CEO, will present on March 15 at noon, when he is expected to discuss the company’s all-in-one site that includes a real-time booking engine for ALR, conventional travel and specialized tours. Omar Jimenez, company CFO, and Richard Marshall, director of corporate development, will also be present.

The presentation will be rebroadcast on the company’s website and will be broadcast live at http://wsw.com/webcast/roth31/mkgi. Kerby, Jimenez, and Marshall will be available for meetings throughout the conference for institutional and individual investors. Meetings can be pre-scheduled through email at OneOnOneRequests@roth.com.

Hundreds of companies are scheduled to make presentations at the ROTH Conference, as well as to participate in question sessions and direct and small group meetings.

ROTH Capital Partners, LLC, is a privately-held investment bank based in Newport Beach, California, that’s focused on emerging companies.

Monaker Group operates the NextTrip.com website, which offers rich content and a library of some 15,000 hours of video that assist travelers in their search for travel destinations and tours. The booking engine offers users the choice of conventional travel, ALR, or specialized tours prepared by a subsidiary of the company. The company has targeted several demographics, and it sees the potential growth of the ALR market, especially for travelers who seek challenging and adventurous trips. Monaker is also focused on business travelers who wish to add additional days for personal travel. Monaker Group aims to capitalize on ALR’s current status as one of the fastest growing sectors of the travel industry.

For more information, refer to www.MonakerGroup.com

The Female Health Company / Veru Healthcare (NASDAQ:FHCO) has established for itself an extremely robust footing in the global public health sector via its hormone-free, latex-free FC2 Female Condom, the only FDA-approved female condom in a market forecast to deliver nine percent plus CAGR over the next five years. The Americas, EMEA and APAC regions alone amount to roughly half a billion plus in revenues already, according to Technavio, and while the Americas’ female condom market accounts for nearly half of the global sum, China and India will most likely drive APAC to out-pace all other regions in terms of growth by a margin of a full one percent or more.

Having originally been founded back in the ’80s during the height of the AIDS epidemic, The Female Health Company’s clear vision of bringing a best-of-breed dual protection product for women to the public health table has now fully blossomed into one of the true frontline weapons in an ongoing struggle against both unwanted pregnancy and the spread of STD/STI (sexually-transmitted disease/infection). An ingenious example of design, the FC2 utilizes a non-latex nitrile sheath that is not only safe to use with oil or water-based lubricants, it also offers increased pleasure potential for both parties, as the material warms from body heat, and possesses a very natural feel. The FC2 also offers a higher rate of protection against unwanted pregnancy and sexually transmitted infection compared to male condoms, meaning that dual-use scenarios where both solutions are deployed often result in a strong additive relationship, leading to a higher overall rate of protected sex among populations.

Empowering women in 144 countries around the world with its FC2 product, FHCO’s combined two decades plus of extensive field experience doing education and distribution programs across the globe has earned the company impeccable credentials within the industry. Whether we are talking about big multilateral entities such as USAID and UNFPA, various national ministries of health, or the key NGOs whose confidence is often the deciding factor between massive contracts or relegation to obscurity. The Female Health Company offers free sexual and reproductive health training materials, as well as FC2 usage training materials, to providers and healthcare professionals via its website (from the same curricula used in FHCO’s worldwide education programs).

Q1 unit sales of the FC2 this year were on par with 2016’s first quarter at around 6.3 million, when you pull out the 9.1 million units attributable to the extraordinarily large Brazil Ministry of Health contract shipments that FHCO fulfilled last year. If you pull out related non-recurring acquisition-related costs and outlays for securing of vital IP, both the Q1 FY17 and FY16 financial data sets look quite good. The company also raked in a $2.8 million payment in early January from its exclusive Brazilian distributor Semina, and it has been informed that more payments on the $13.1 million outstanding ($7.8 million in 2016 invoices alone) are forthcoming for FY17. Quarter-to-quarter fluctuations are par for the course here and are related to timing and shipping of sizable orders, but the underlying fundamentals are solid, as is product throughput to end markets.

The overall success of the FC2 really primed FHCO for its transformational merger with Aspen Park Pharmaceuticals, Inc. (APP) late last year in October, which added a multi-faceted forward window to the company’s revenue profile in the form of APP’s attractive portfolio of men’s health-focused pharmaceuticals and consumer health indications. FHCO will be doing business as Veru Healthcare subsequent to the merger when it comes to pharmaceuticals for men’s and women’s health and oncology, as well as for consumer health and medical devices (as opposed to the division using the corporate name brand, The Female Health Company, which will oversee FC2 when it comes to the public health market). This distinct division, Veru Healthcare, will also deploy the company’s proprietary female condom as the FC2 Female Condom in the consumer health market and Female Disposable Contraceptive Device (FC2) in the U.S. prescription market.

President and CEO of FHCO, Mitchell Steiner, MD, certainly projected confidence about the company’s revenue growth-initiating merger last month, when FHCO released its Q1 FY17 financials, and noted of FC2 that it was “without equal” when it comes to contraceptive products for women who want to defend against both pregnancy and STDs. With HIV/AIDS still the top killer of women aged 15 to 44 globally, and around 80 percent of cases occurring via heterosexual transmission, the sheer utility of a product like the FC2, which can be inserted anywhere from hours or just minutes in advance of sexual intercourse, is unquestionable, particularly in at-risk populations like sex workers, where the existence of a female-use driven, dual-protectant product like the FC2 can potentially work wonders. Research has even shown substantial indirect healthcare cost benefits to the implementation of female condom programs, with two to three times return multiples on every dollar invested in countries such as Cameroon and Nigeria.

Solid financials and a healthy logistical footprint, as essentially a preferred provider in the public health/female condom market, amply supports FHCO’s expansion/growth strategy, and it is noteworthy how shrewd a move this is from a PR standpoint for a company already so well established in women’s health. Branching out boldly into pharmaceuticals with a focus on men’s health through Veru Healthcare is marketing gold, and with such IP-reinforced, exciting sexual health products for men as PREBOOST® in the pipeline (an OTC-available, convenient, discreet, medicated individual wipe designed to curb premature ejaculation), serious multi-pronged revenue growth may be on the near horizon for FHCO.

A disposable, pre-moistened wipe that employs a highly effective yet safe topical anesthetic, PREBOOST was designed by Clinical Professor of Urology and Reproductive Medicine at New York Presbyterian Hospital/Weill Medical College of Cornell University Dr. Fisch to solve application problems associated with industry-standard creams and sprays, while simultaneously providing powerful, yet subtle, skin desensitization. Available in easy to carry single-use packets, roughly the size of an individually-wrapped condom, PREBOOST is easy to apply without mess, and it doesn’t interfere with the pleasure from an orgasm.

The company has already sought Orphan Drug status from the FDA for its MSS-722, a patented and proprietary treatment for male infertility that would be the first orally-available option for such indications to come to market (only currently FDA-approved standard is HCG/FSH injections). The company is in a very good position here as the Trump administration moves to speed up the new drug approval process, and MSS-722 can effectively piggyback on extant clinical and nonclinical data for CLOMID (clomiphene citrate) tablets, which are currently being used as first line therapy in 90 percent of idiopathic (having an unknown pathogenesis, or spontaneous origin) infertile men. With a nice guidance follow up late last year in December to the company’s earlier pre-IND meetings with the FDA, FHCO is now gearing up for Phase 2 clinical trials of MSS-722 and expects an NDA filing sometime in 2019.

Another near-term viability (NDA expected this year) indication picked up under the merger is Tamsulosin DRS, a delayed-release sachet, novel oral powder-like formulation targeting Benign Prostatic Hyperplasia (BPH), which is set to hit $4.9 billion by 2024, according to research and consulting firm GlobalData, over which time the space will cook along at an impressive 8.23 percent CAGR. Tamsulosin DRS contains the same API (active pharmaceutical ingredient) as Tamsulosin hydrochloride, developed by Astellas (OTC: ALPMY; ALPMF) and typically marketed in the U.S. under the trade name FLOMAX®, for BPH, or enlarged prostate. A new formulation here by FHCO would knock directly on the front door of the roughly $3.5 billion domestic generic/FLOMAX market, as well as address the broader $4.5 billion (QuintilesIMS) U.S. BPH alpha blocker space. The development strategy here should seem familiar to readers, as FHCO can once again utilize extant safety and efficacy data (in this case FLOMAX data), in order to significantly benefit shareholders.

Also in the pipeline from FHCO’s Veru Healthcare division are APP-944 for hot flashes in men undergoing prostate cancer hormone therapy, which would be the first approved oral drug in this area (NDA expected in 2020), and two more oral drugs slated to NDA in 2022, APP-111/APP-112. The first of these, APP-111, is a third line hormonal therapy for advanced prostate cancer with phase 1 studies planned to take place in 2018. This will lead directly to an IND filing and APP-112 studies in gout (the most common form of inflammatory arthritis in men) the following year.

FHCO is making all the right moves to wrangle a revenue growth herd through the Veru Healthcare portfolio, and this growth strategy seems to have been marvelously handcrafted by management. Moreover, the company has recently executed a series of key appointments in support of its growth strategy, from the most recent tapping of 20-year veteran analytical chemist Matthew C. Gosnell, Ph.D. for the Senior V.P. of Manufacturing role, to the appointment in January of sales and marketing heavyweight Brian J. Groch (who has over three decades in pharma and biotech) as the company’s new CCO.

To learn more, visit www.veruhealthcare.com or www.fc2femalecondom.com

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion.

For more information, visit the company’s website at www.InMedPharma.com

The smartphone has become the computer we carry with us everywhere, and it has changed the way the world transacts business. Smartphones are now powerful mini-computers, personal assistants, and mobile shopping carts. From the advent of the smartphone 10 years ago, there are now an estimated 4.8 billion users globally. In just over a decade, these ubiquitous devices have created transformational business opportunities. The mobile payments industry is flourishing from this growth.

By 2014, 14 percent of all mobile users in the U.S. had made a mobile payment, and a year later it was 39 percent. Some estimates suggest that over 60 percent of U.S. mobile users will utilize mobile payments by the end of this year. Globally, the growth numbers are even more impressive. The mobile payments industry is profiting as it meets the surging demands of users.

Even before 2012, when Net Element’s (NASDAQ: NETE) subsidiary was recognized as one of the fastest growing companies in America, the company was at the vanguard of global mobile payment solutions. Net Element enables global commerce by providing merchants electronic payment solutions to process transactions through the company’s various integrated platforms. The company owns and operates TOT Group, a global mobile payments processing provider, and Aptito, a cloud-based point of sale payments platform. The company also owns and operates one of the leading providers of SMS messaging and mobile billing solutions, Digital Provider, and a fully-integrated electronic commerce platform, PayOnline.

Net Element has established partnerships with American Express, MasterCard, Discover, Visa, and other international financial institutions to meet the expansive needs of a global customer base. The company has continued to enjoy success and was recently recognized as one of the Top 25 Fastest-Growing Technology Companies by the South Florida Business Journal in 2016.

Technology has dramatically altered the way we transact business over the last 10 years. The planet is moving to mobile payments, and Net Element offers a way to profit from this transition.

For more information, visit www.NetElement.com

Health care costs in the U.S. have been rising rapidly over the decades and data provided by the Kaiser Family Foundation (http://dtn.fm/Xfs0F) show the extent of that rise. In 1960, total national expenditure on health care was $27.2 billion, amounting to 5 percent of GDP. In 2015, it had climbed to $3.2 trillion, increasing by an astounding 11,785 percent to 17.8 percent of National Income (GDP). The causes are diverse: a combination of factors that include greater demand for health services and a population that is living longer. But the solutions have been less obvious. Now, ORHub, Inc. (OTC: ORHB) is offering a digital platform it believes will substantially lower costs. The ORHub system significantly decreases cost and improves outcomes by eliminating inefficiencies, duplication of effort, and errors and omissions that result from siloed processes in software and poor handoffs from one part of the care process to another.

At present, many of the systems that handle accountability, billing and inventory management in the 150 million annual surgical operations are manual. Consequently, processing takes a long time, with large numbers of unhappy vendors having to wait for 90 or 120 days to get paid. In addition, manual systems are labor intensive, requiring high-cost staff, but many back-office processes in the health care information management system can be handled faster and with less error by automation.

A McKinsey study (http://dtn.fm/2RwJg) demonstrates the extent of the problem. It reports that ‘fifteen cents of every US healthcare dollar go toward revenue cycle inefficiencies’. That would mean close to half a trillion dollars ‘go to claims processing, payments, billing, revenue cycle management (RCM), and bad debt—in part, because half of all payor-provider transactions involve outdated manual methods, such as phone calls and mailings.’ The study warns that for hospitals to survive requires ‘aggressive automation’.

However, RCM IT systems cost a packet. For example, Scripps Health, a nonprofit health care system, recently ‘spent nearly $19.9 million on software and hardware to make the switch to ICD-10’ (http://dtn.fm/h9ImE). ICD-10 is a medical classification system for diseases and related health problems.

The San Diego, California-based provider, which operates four hospitals and 19 outpatient facilities and treats half a million patients annually through 2,600 affiliated physicians, expects to expend $360.5 million over the next 10 years to upgrade its inpatient and ambulatory electronic health record (EHR) and revenue cycle management (RCM) systems. Faced with such financial hurdles, hospitals and other health care providers are likely to turn to cloud-based solutions. McKinsey expects ‘that RCM outsourcing will take off over the next several years— potentially, up to 40 percent of providers may consider end-to-end outsourcing in the near future’.

ORHub already has its foot in the door of this market. The production version of the first release of its digital platform is currently in daily use at two regional hospitals. ORHub plans to gain a dominant share of the surgical market. The company estimates the segment at about 150 million surgeries annually, a number that is expected to grow with demographic trends.

The company will focus its marketing efforts on major national hospital operations. Even though there are around 5,600 hospitals in the United States, 80% of surgeries are performed by the top 12 hospital ownership groups and performed at the 1,100 largest surgical hospitals.

ORHub is transforming the business of surgery. By creating a new category of health care IT vertical-specific software known as Surgical Resource Management, the company is offering enhanced capabilities over traditional EHR solutions in the operating room. The ORHub platform, which employs Microsoft’s Azure Cloud, is at present the subject of a study in which its impact on participating institutions is being assessed. The study, funded by Microsoft and Intel, will be concluded sometime in Q2 2017.

For more information, visit the company’s website at www.ORhub.com

When Christopher Columbus introduced the pineapple to Europe in the late fifteenth century, he undoubtedly would have had no idea that extracts from the plant could be used to treat severe thermal burns. Yet, 500 years later, a next-generation proteolytic enzyme platform for wound debridement, NexoBrid, derived from pineapples, has been developed by MediWound Ltd. (NASDAQ: MDWD). Now, positive results from a Phase II study evaluating NexoBrid will be used to support a request to the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to extend the label for NexoBrid to larger burns. The painstaking research undertaken by niche specialty biotech MediWound is beginning to bear fruit.

That research has laid bare one ‘secret’ of the medicine practiced traditionally by natives of South and Central America and developed on it to improve the treatment of wounds. Pineapples, it turns out, are a rich source of proteolytic enzymes, referred to generally as bromelain, which promote healing in wounds by stimulating debridement, the removal of dead tissue and foreign material. Proteolytic enzymes remove this necrotic tissue, known as eschar, at a much faster rate than would occur otherwise. To harness this powerful chemical process, MediWound has developed its proteolytic enzyme platform. NexoBrid is a concentrate derived from a mixture of proteolytic enzymes extracted from the stem of the pineapple plant, enriched in bromelain. The drug is indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns.

Last month, MediWound announced positive results from a Phase II study that evaluated the safety, pharmacokinetics (transcutaneous absorption) and efficacy of NexoBrid in hospitalized children and adults with severe thermal burns. The multicenter, open-label, single-arm study was conducted in Europe, Israel and India and included 36 patients with severe burns of 4 percent to 30 percent total body surface area (TBSA).

NexoBrid was applied to burns of up to 15 percent TBSA in one session, and when the wound area to be treated was more than 15% TBSA, NexoBrid was applied in two separate sessions, each up to 15 percent TBSA. Trial results showed that the use of NexoBrid was safe and effective. Furthermore, the pharmacokinetic profile following NexoBrid’s first and second topical application was comparable, suggesting no concern with accumulation following a second topical application of NexoBrid. As a result, the company intends to send requests to the FDA and EMA to extend the label for NexoBrid to larger burns.

MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. Its first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns and has already been launched in Europe.

MediWound’s second innovative product, EscharEx®, is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds, a large and growing market. EscharEx® is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx®contains the same proteolytic enzyme technology as NexoBrid® and benefits from the wealth of existing development data on NexoBrid®.

Aegis Capital, which initiated coverage on MediWound late last year, has issued a ‘Buy’ rating on the stock, setting a price target of $11.00. The stock, under the symbol MDWD, currently trades on the NASDAQ at around $6.00.

For more information, visit www.MediWound.com

For companies trying to keep up with technology, social media, interactive customer acquisition, and customer loyalty programs, all while trying to grow a brick and mortar business, it can be a daunting task. To attract new customers on multiple interactive levels can require hiring entire departments of personnel to set up, organize, and execute effective strategies. It can be costly, time consuming, and require ongoing management. In Asia, more and more small- and medium-sized businesses are turning to Moxian (NASDAQ: MOXC) for turnkey solutions to all of these challenges.

Moxian operates a social network platform that integrates social media and business into a single platform and offers products, features, and services to attract and maintain customers. The company’s online platforms and mobile applications, the Moxian+ User app and the Moxian+ Business app, allow businesses to interface with both existing and new customers. These interactions provide each business the data to analyze consumer likes, dislikes, and trends. Moxian’s platform gives businesses the ability to create, manage, and promote individualized customer loyalty programs, targeted advertising campaigns, and special promotions. It allows small to mid-sized companies to single source their social media marketing while creating new customers.

With offices strategically located in China, Malaysia, and Hong Kong, Moxian is positioned to benefit from one of the world’s fastest growing consumer markets. According to a China Daily cited 2015 study (http://nnw.fm/I9b84) done by Boston Consulting Group and the research arm of Alibaba Group, AliResearch, China is projected to remain one of the world’s fastest-growing consumer markets through 2020, reaching $6.5 trillion in annual private consumption even if annual GDP growth slows to 5.5 percent over the next five years. The report also stated that because of the nature of consumer consumption changes, which are dramatic, the winning strategies of the past are becoming outdated, and it’s more important than ever for businesses to make good strategic decisions in the way they target and attract consumers. Moxian provides businesses the strategic solutions to target and attract new customers in a booming marketplace.

For more information, visit www.Moxian.com

India Globalization Capital, Inc. (NYSE MKT: IGC) is a company in transition, now targeting pharmaceutical development in the U.S., while curtailing other businesses such as electronics trading in Hong Kong. IGC long-term plans are to establish and extend its development of phytocannabinoid-based pharmaceutical products to treat diseases such as epilepsy and cachexia. The company expects to file more patents and develop additional intellectual property in the health care industry.

In the U.S., IGC develops phytocannabinoid-based treatments for epilepsy, seizures and cachexia. The goal in 2017, per CEO Ram Mukunda, is for the company to expand its cannabis-based portfolio, indicating that IGC will begin preclinical trials of IGC-501-Pain, IGC-502-Seizures and IGC-504-Cachexia (http://dtn.fm/bv91H). The company has formed a Phytocannabinoid Development Committee to review global medical facilities prior to beginning its preclinical trials. Toxicity evaluation and pharmacological assessments will be performed on each compound in preclinical trials.

Based in Bethesda, Maryland, IGC also manages real estate, leasing and development of properties. In India, it leases heavy equipment. In Malaysia, it manages commercial and residential real estate. In Hong Kong, the company previously operated a electronics business, but it has subsequently moved away from that activity. Long term, IGC aims to establish itself as a specialty pharmaceutical provider. It has already filed five provisional patents for its phytocannabinoid-based pharmaceutical and nutraceutical products in the U.S.

For more information, please refer to www.IGCInc.us

On Wednesday, Pressure BioSciences, Inc. (OTCQB: PBIO) announced that it has received the award for ‘Best New Instrument For Sample Preparation 2017’ from Corporate America News (http://dtn.fm/CAg47) for its Barocycler 2320Extreme.

The unit is the most recent product added to PBIO’s Barocycler line. It is a smaller device designed for preparing protein samples for review. It is sold to the life science market, which is valued at roughly $6 billion, according to industry data.

Pressure BioSciences, Inc. develops and sells laboratory instrumentation. It manufactures products in static and alternating pressure. The company says it has installed more than 250 of its systems in 160 sites globally. While its focus is on forensics and biomarker discovery, its products are also utilized in vaccine manufacturing and drug discovery, design and histology.

The award was given to PBIO by Corporate America News as part of its 2017 North American Excellence Awards. Targeting the U.S. business market, the magazine has a circulation of some 135,000.

“We are honored to have been selected for this prestigious award,” Dr. Nate Lawrence, PBIO’s VP of marketing and sales, stated in a news release. “It was just eight months ago when we launched this next-generation Barocycler instrument, the EXT 2320. Since then, the instrument has been purchased by key scientists in academic, government, biotech and pharma labs worldwide, including institutions involved in the Cancer Moonshot Initiative. We believe this award affirms the significant potential of the Barocycler 2320.”

Richard T. Shumacher, president and CEO of PBIO, described in the magazine the specific features and benefits of the Barocycler 2320Extreme. He also discussed the history of the company and its future growth potential.

“In addition to our patented and cutting edge technology platform, we have both a hard-working, results-driven management and support team, and an experienced and supportive Board of Directors,” Shumacher said. “We believe that the combination of these factors will help ensure the success of our company with a concomitant strong return-on-investment for stakeholders in [PBIO].”

For more information, visit www.PressureBiosciences.com